IP Library Granted Patent US 10,100,124
Granted Patent B2
US 10,100,124 · App. 14/970,181 · Granted Oct 16, 2018

Antibodies directed to HER-3 and uses thereof

Inventors: Mike Rothe (Krailling, DE); Martin Treder (Zurich, CH); Eric Borges (Maria Enzersdorf, AT); Susanne Hartmann (Munich, DE); Larry L. Green (Pasadena, CA)
Assignees: Daiichi Sankyo Europe GmbH; AMGEN, INC.
C07K16/32C07K16/2863G01N33/574A61K2039/505A61K2039/507C07K2317/14C07K2317/21C07K2317/33C07K2317/34C07K2317/73C07K2317/76C07K2317/77C07K2317/92C12N15/00C12N15/09C12N15/63C12N2800/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,100,124
App. No.
14/970,181
Granted
Oct 16, 2018
Kind
B2
Abstract

The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.

Claims (28)

1. An isolated nucleic acid molecule, or a plurality of isolated nucleic acid molecules, each encoding a binding protein that binds to HER-3, comprising

(a) (i) a nucleic acid encoding a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:236, a CDRH2 having the sequence of SEQ ID NO:258, and a CDRH3 having the sequence of SEQ ID NO:283; and (ii) a nucleic acid encoding a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:320, a CDRL2 having the sequence of SEQ ID NO:343, and a CDRL3 having the sequence of SEQ ID NO:360;

(b) (i) a nucleic acid encoding a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:236, a CDRH2 having the sequence of SEQ ID NO:258, and a CDRH3 having the sequence of SEQ ID NO:285; and (ii) a nucleic acid encoding a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID No:320, a CDRL2 having the sequence of SEQ ID NO:343, and a CDRL3 having the sequence of SEQ ID NO:360;

(c) (i) a nucleic acid encoding a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:251, a CDRH2 having the sequence of SEQ ID NO:278, and a CDRH3 having the sequence of SEQ ID NO:309; and (ii) a nucleic acid encoding a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:334, a CDRL2 having the sequence of SEQ ID NO:356, and a CDRL3 having the sequence of SEQ ID NO:381;

(d) (i) a nucleic acid encoding a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:252, a CDRH2 having the sequence of SEQ ID NO:280, and a CDRH3 having the sequence of SEQ ID NO:313; and (ii) a nucleic acid encoding a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:337, a CDRL2 having the sequence of SEQ ID NO:351, and a CDRL3 having the sequence of SEQ ID NO:385; or

(e) (i) a nucleic acid encoding a heavy chain amino acid sequence that comprises a CDRH1 having the sequence of SEQ ID NO:256, a CDRH2 having the sequence of SEQ ID NO:282, and a CDRH3 having the sequence of SEQ ID NO:315; and (ii) a nucleic acid encoding a light chain amino acid sequence that comprises a CDRL1 having the sequence of SEQ ID NO:340, a CDRL2 having the sequence of SEQ ID NO:344, and a CDRL3 having the sequence of SEQ ID NO:387.

2. The isolated nucleic acid molecule, or plurality of isolated nucleic acid molecules, of claim 1 , wherein each nucleic acid molecule is operably linked to a control sequence.

3. One or a plurality of vectors, wherein each vector comprises a nucleic acid molecule of claim 1 .

4. One or a plurality of isolated host cells transformed with the vector, or the plurality of vectors, of claim 3 .

5. A process for preparing a binding protein that binds to HER-3, comprising (1) providing one or a plurality of isolated host cells comprising one or a plurality of nucleic acid molecules of claim 1 ; and (2) isolating said binding protein from said host cell(s).

6. The process of claim 5 , wherein the one or plurality of isolated host cells are mammalian cells, plant cells, fungal cells, or prokaryotic cells.

7. An isolated nucleic acid molecule, or a plurality of isolated nucleic acid molecules, each encoding a binding protein that binds to HER-3, comprising

(a) a nucleic acid encoding the heavy chain amino acid sequence of SEQ ID NOs:42 and a nucleic acid encoding the light chain amino acid sequence of SEQ ID NOs:44;

(b) a nucleic acid encoding the heavy chain amino acid sequence of SEQ ID NO:54, and a nucleic acid encoding the light chain amino acid sequence of SEQ ID NO:56;

(c) a nucleic acid encoding the heavy chain amino acid sequence of SEQ ID NO:70, and a nucleic acid encoding the light chain amino acid sequence of SEQ ID NO:72;

(d) a nucleic acid encoding the heavy chain amino acid sequence of SEQ ID NO:92, and a nucleic acid encoding the light chain amino acid sequence of SEQ ID NO:94; or

(e) a nucleic acid encoding the heavy chain amino acid sequence of SEQ ID NO:96, and a nucleic acid encoding the light chain amino acid sequence of SEQ ID NO:98.

8. The isolated nucleic acid molecule, or plurality of isolated nucleic acid molecules, of claim 7 , wherein each nucleic acid molecule is operably linked to a control sequence.

9. One or a plurality of vectors, wherein each vector comprises a nucleic acid molecule of claim 7 .

10. One or a plurality of isolated host cells transformed with the vector, or plurality of vectors, of claim 9 .

11. A process for preparing a binding protein that binds to HER-3, comprising (1) providing one or a plurality of isolated host cells comprising one or a plurality of nucleic acid molecules of claims 7 ; and (2) isolating said binding protein from said host cell(s).

12. The process of claim 11 , wherein the one or plurality of isolated host cells are mammalian cells, plant cells, fungal cells, or prokaryotic cells.

13. An isolated nucleic acid molecule, or a plurality of isolated nucleic acid molecules, each encoding a binding protein that binds to HER-3, comprising (1) a nucleic acid molecule encoding the heavy chain amino acid sequence of SEQ ID:70, and (2) a nucleic acid molecule encoding the light chain amino acid sequence having the sequence of SEQ ID NO: 72.

14. The isolated nucleic acid molecule, or plurality of nucleic acid molecules, of claim 13 , wherein each nucleic acid molecule is operably linked to a control sequence.

15. One or a plurality of vectors, wherein each vector comprises a nucleic acid molecule of claim 13 .

16. One or a plurality of isolated host cells transformed with the vector, or plurality of vectors, of claim 15 .

17. A process for preparing a binding protein that binds to HER-3, comprising (1) providing one or a plurality of isolated host cells comprising one or a plurality of nucleic acid molecules of claim 13 ; and (2) isolating said binding protein from said host cell(s).

18. The process of claim 17 , wherein the one or plurality of isolated host cells are mammalian cells, plant cells, fungal cells, or prokaryotic cells.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Mar 16, 2017
From: U3 PHARMA GMBH; DAIICHI SANKYO EUROPE GMBH
To: DAIICHI SANKYO EUROPE GMBH
Reel/Frame 042032/0351 →
Continuity (4)
Continuation 12365784 · Feb 4, 2009
Division 11649722 · Jan 3, 2007
Provisional Application 60755103 · Dec 30, 2005
Related Publication 20160168264A1 · Jun 16, 2016